Medical institutions like the Dana-Farber Cancer Institute have established dedicated clinical programs to investigate the biological drivers behind cases occurring in patients under 50.
Clinical Trials Targeting Young-Onset Colorectal Cancer Treatments
Clinical trials provide access to cutting-edge interventions for younger patient populations. According to the Dana-Farber Cancer Institute, physicians evaluate patients under 50 for clinical trials testing targeted therapies such as KRAS inhibitors and novel chemotherapies including antibody-drug conjugates. Researchers also utilize the institute’s Cell Therapies Program to explore immunotherapy options, including CAR T-cell therapy, for colorectal cancer. Beyond drug therapy, ongoing clinical studies examine lifestyle variables like diet and exercise.
Microbiome Research and Living Biobanks
Researchers are increasingly focusing on the gut microbiome to understand why early-onset rates continue to climb. According to Dana-Farber, the human microbiome consists of microorganisms that aid bodily functions, but an imbalance can influence how colorectal cancers develop and impact immunotherapy efficacy. Investigators in the Young-Onset Colorectal Cancer Center compare microbiomes between younger and older patients to discover targets for future vaccines, antibiotics, and microbe transfers.
To support personalized treatment development, major centers rely on living biobanks. During biopsies or surgeries, patients can consent to store anonymous tumor tissue samples in a repository. According to Dana-Farber, researchers analyze these biospecimens to map the biological characteristics of individual cancers and identify the most promising treatments for upcoming clinical trials.
Patient Participation Options
Patients seeking to contribute to early-onset research have multiple avenues for participation. According to Dana-Farber, individuals treated at the institute or partner locations can join specialized institutional studies by providing clinical data alongside blood, stool, and tumor samples, coupled with dietary questionnaires. Alternatively, patients across the United States and Canada can participate in the Count Me In research project to accelerate data collection and sample sharing.
Related reading